Resources from the same session
46MO - What are the predictors of the success of interval debulking surgery (CC0-IDS) in patients with advanced ovarian cancers? Consistent data from two large independent datasets
Presenter: Adriana Apostol
Session: Mini Oral session 2
Resources:
Abstract
Slides
Webcast
47MO - The risk index of early relapse defined by MiROvaR, a miRNA-based classifier, is a potential predictive marker for bevacizumab benefit: A MITO-MANGO-ENGOT study
Presenter: Marina Bagnoli
Session: Mini Oral session 2
Resources:
Abstract
Slides
Webcast
48MO - Treatment and outcome of elderly patients with advanced ovarian cancer in Germany: QS-OVAR of the AGO Study Group
Presenter: Felix Hilpert
Session: Mini Oral session 2
Resources:
Abstract
Slides
Webcast
Invited Discussant abstracts 46MO, 47MO and 48MO
Presenter: Robert Coleman
Session: Mini Oral session 2
Resources:
Slides
Webcast
Q&A
Session: Mini Oral session 2
Resources:
Webcast
49MO - Updated progression-free survival (PFS) in patients (pts) with newly diagnosed advanced ovarian cancer (OC) treated with rucaparib (RUC) in ATHENA-MONO
Presenter: Rebecca Kristeleit
Session: Mini Oral session 2
Resources:
Abstract
Slides
Webcast
41MO - ESR1 mutation in untreated endometrial cancer: Prevalence, characteristics and prognostic implications from the UTOLA trial
Presenter: Felix Blanc-Durand
Session: Mini Oral session 2
Resources:
Abstract
Slides
Webcast
42MO - Interpreting somatic POLE mutations in endometrial cancer emerging from comprehensive genomic profiling
Presenter: Rita Trozzi
Session: Mini Oral session 2
Resources:
Abstract
24MO - TROP-2, TF and NECTIN4 as targets for ADC treatment in cervical cancer
Presenter: Mari Halle
Session: Mini Oral session 2
Resources:
Abstract
Slides
Webcast
Invited Discussant abstracts 49MO, 41MO, 42MO and 24MO
Presenter: Ioana Braicu
Session: Mini Oral session 2
Resources:
Slides
Webcast